Full Text View
Tabular View
No Study Results Posted
Related Studies
Lanreotide as Treatment of Polycystic Livers (LOCKCYST)
This study has been completed.
Study NCT00565097   Information provided by Radboud University

First Received on November 28, 2007.   Last Updated on February 16, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Polycystic Liver Disease
Hepatomegaly
Liver Diseases
Additional conditions recognized in this trial
Cysts
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
More general conditions related to this trial
Digestive System Diseases
Hypertrophy
Kidney Diseases
Kidney Diseases, Cystic
Neoplasms
Pathological Conditions, Anatomical
Urologic Diseases
Interventions listed in this trial
Placebo
Lanreotide
Additional drug interventions recognized in this trial
Angiopeptin
More general drug interventions related to this trial
Antineoplastic Agents
Cardiovascular Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Radboud University
Ipsen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services